Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Musto, Pellegrino  [Clear All Filters]
2024
Sgherza N, Mestice A, Larocca AMaria Vitt, Musto P. Antibody Response to Breakthrough SARS-CoV-2 Infection in "Booster" Vaccinated Patients with Multiple Myeloma According to B/T/NK Lymphocyte Absolute Counts and anti-CD38 Treatments. Mediterr J Hematol Infect Dis. 2024;16(1):e2024022.
2023
Terpos E, Musto P, Engelhardt M, Ntanasis-Stathopoulos I, Sonneveld P, Ludwig H. Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensus. Leukemia. 2023.
Bavaro DFiore, Diella L, Belati A, Metrangolo G, De Santis L, Spada V, Camporeale M, Dargenio A, Brindicci G, Balena F, et al. Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study. Viruses. 2023;15(5).
Nizzoli ME, Manni M, Ghiggi C, Pulsoni A, Musuraca G, Merli M, Califano C, Bari A, Massaia M, Conconi A, et al. Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. Hematol Oncol. 2023.
Minoia C, Diella L, Perrone T, Loseto G, Pelligrino C, Attolico I, Pasciolla C, Totaro V, De Candia MStella, Spada V, et al. Oral anti-viral therapy for early COVID-19 infection in patients with haematological malignancies: A multicentre prospective cohort. Br J Haematol. 2023.
Ludwig H, Terpos E, van de Donk N, Mateos M-V, Moreau P, Dimopoulos M-A, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255-e269.
Gaudio F, Dicataldo M, Di Giovanni F, Cazzato G, d'Amati A, Perrone T, Masciopinto P, Laddaga FEmanuela, Musto P, Maiorano E, et al. Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2023.
Gaudio F, Loseto G, Bozzoli V, Scalzulli PRosario, Mazzone AMaria, Tonialini L, Fesce V, Quintana G, De Santis G, Masciopinto P, et al. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma. Ann Hematol. 2023.
Musto P, Salmanton-García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, Seval GCengiz, Weinbergerova B, Bonuomo V, Bilgin YM, et al. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry. Hematol Oncol. 2023.
Cumbo C, Orsini P, Tarantini F, Anelli L, Zagaria A, Tragni V, Coccaro N, Tota G, Parciante E, Conserva MRosa, et al. TNFRSF13B gene mutation in familial acute myeloid leukemia: A new piece in the complex scenario of hereditary predisposition?. Hematol Oncol. 2023.
van de Donk NWCJ, Minnema MC, van der Holt B, Schjesvold F, Wu KLung, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, et al. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. Lancet Oncol. 2023.
2022
Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, de Rosa L, et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2022.
Marasco V, Piciocchi A, Candoni A, Pagano L, Guidetti A, Musto P, Bruna R, Bocchia M, Visentin A, Turrini M, et al. Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study. Br J Haematol. 2022.
Isidori A, Loscocco F, Visani G, Paolasini S, Scalzulli P, Musto P, Perrone T, Guarini A, Pastore D, Mazza P, et al. Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients. Br J Haematol. 2022.
2021
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, et al. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. Eur J Haematol. 2021.
Delia M, Carluccio P, Mestice A, Chiusolo P, Metafuni E, Bellesi S, Arpinati M, Milone GAntonio, Martino M, Mazza P, et al. The impact of graft CD3/Tregs ratio on aGvHD and post-transplant outcome: a prospective multicenter study on patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation. Transplant Cell Ther. 2021.
2020
Tacchetti P, Pantani L, Patriarca F, Petrucci MTeresa, Zamagni E, Dozza L, Galli M, Di Raimondo F, Crippa C, Boccadoro M, et al. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematol. 2020;7(12):e861-e873.
2019
D'Arena G, Valvano L, Vitale C, Coscia M, Statuto T, Bellesi S, Lamorte D, Musto P, Laurenti L, D'Auria F. CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results. Leuk Res. 2019;83:106169.
Statuto T, Valvano L, Calice G, Villani O, Pietrantuono G, Mansueto G, D'Arena G, Vita G, Lalinga V, Possidente L, et al. Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients. Leuk Res. 2019;88:106267.
2018
Todoerti K, Calice G, Trino S, Simeon V, Lionetti M, Manzoni M, Fabris S, Barbieri M, Pompa A, Baldini L, et al. Global methylation patterns in primary plasma cell leukemia. Leuk Res. 2018;73:95-102.
D'Arena G, Seneca E, Migliaccio I, De Feo V, Giudice A, La Rocca F, Capunzo M, Calapai G, Festa A, Caraglia M, et al. Oxidative stress in chronic lymphocytic leukemia: still a matter of debate. Leuk Lymphoma. 2018:1-9.
2016
Musto P, Simeon V, Todoerti K, Neri A. Primary Plasma Cell Leukemia: Identity Card 2016. Curr Treat Options Oncol. 2016;17(4):19.
2015
D'Arena G, Grandone E, Di Minno MNicola Dar, Musto P, Di Minno G. Acquired hemophilia a successfully treated with rituximab. Mediterr J Hematol Infect Dis. 2015;7(1):e2015024.
D'Arena G, Grandone E, Di Minno MND, Musto P, Di Minno G. The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. Blood Transfus. 2015:1-7.
De Luca L, Trino S, Laurenzana I, Simeon V, Calice G, Raimondo S, Podestà M, Santodirocco M, Di Mauro L, La Rocca F, et al. MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation. Oncotarget. 2015.

Pages